Isolation of T cell receptors specifically reactive with mutated tumor associated antigens by Maria Parkhurst et al.
POSTER PRESENTATION Open Access
Isolation of T cell receptors specifically reactive
with mutated tumor associated antigens
Maria Parkhurst*, Paul Robbins, Steven Rosenberg
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Background and hypotheses
The adoptive transfer of tumor infiltrating lymphocytes
(TIL) can mediate the regression of metastatic melanoma
[1]. In addition, the adoptive transfer of lymphocytes
expressing T cell receptors (TCRs) specifically reactive with
antigens expressed on melanoma cells can mediate tumor
regression [2]. Many T cells from TIL recognize mutated
antigens expressed only on the autologous patient’s tumor
cells [3]. Therefore, we have attempted to isolate TCRs
reactive with unique mutated antigens so that we may
eventually treat patients with autologous T cells that have
been genetically modified to express those TCRs.
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Table 1 IFNg secretion (pg/ml) by TCR transduced PBL
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a CD8+ PBL from patient 3713 were stimulated in vitro with mature autologous DCs pulsed with mutated peptides predicted to bind with high affinities to
HLA-A*0201 and were restimulated twice with autologous peptide-pulsed PBMCs. Recognition of relevant target cells was evaluated on the basis of IFNg
secretion after overnight coculture. 2 peptides, one derived from a mutation in the AHNAK protein and one derived from a mutation in the SRPX protein,
stimulated T cells that specifically recognized peptide, COS7 cells expressing HLA-A*0201 that had been transfected with the relevant minigene, and the
autologous tumor cell line.
b TIL from patient 3713 were cocultured overnight with autologous DCs electroporated with in vitro transcribed (IVT) RNA encoding a fragment of the mutated
SRPX protein. CD3+ CD8+ 41BB+ cells were sorted by FACS and expanded in the presence of allogeneic feeder cells, a-CD3, and IL2. The resulting T cell
population specifically recognized peptide, COS7 cells expressing HLA-A*0201 that had been transfected with the relevant minigene, and the autologous tumor
cell line.
c TCR a and b chains in T cell populations were identified by 5’ RACE using degenerate constant region primers and were cloned into retroviral vectors. These
were then used to transduce PBL from patient 3713, and the function of the resulting genetically modified T cells was evaluated on the basis of IFNg secretion
after overnight coculture.
d HBV: hepatitis B core virus peptide used as a negative control with high binding affinity to HLA-A*0201.
e AHNAK: neuroblast differentiation-associated protein, also known as desmoyokin.
f SRPX: sushi repeat-containing protein.
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Study design and methods
Exome sequencing and RNA sequencing were used to
identify mutated antigens that are highly expressed in
tumors. In this study, we used 2 methods to isolate TCRs
reactive with mutated antigens as follows:
1. TIL were stimulated overnight with autologous den-
dritic cells (DCs) electroporated with in vitro transcribed
RNAs encoding mutations. CD3+ CD8+ T cells that had
upregulated CD137 after stimulation were then FACS
sorted and expanded in vitro with anti-CD3 and IL2.
2. Peptides encompassing mutations with high pre-
dicted binding affinities to HLA-A*0201 were used to
stimulate peripheral blood lymphocytes (PBL) from
autologous patients expressing this HLA molecule. PBL
were stimulated in vitro with peptide-pulsed autologous
mature DCs and restimulated 7-10 days later with pep-
tide-pulsed autologous PBMCs. T cells that upregulated
CD137 after stimulation with 239 or COS cells expres-
sing HLA-A*0201 and the mutation were then sorted
and expanded in vitro with anti-CD3 and IL2. Recogni-
tion of appropriate target cells by the resulting T cell
populations was evaluated on the basis of IFNg secretion
and CD137 expression. For populations which appeared
to be enriched for T cells capable of recognizing
mutated antigens, TCR a and b chain sequences were
identified using 5’ RACE, and retroviruses encoding
those TCRs were used to transduce PBL.
Results and conclusions
Using these techniques, we identified, enriched, and
expanded T cell populations that recognized mutated
tumor associated antigens. We also identified dominant
TCR a and b chains in these enriched populations. By
using retroviruses encoding the dominant TCRs to trans-
duce human PBL, we demonstrated that these TCRs
mediated recognition of the expected tumor associated
mutated antigens (Table 1). We are currently attempting
to develop clinical reagents to treat patients with TCRs
that recognize unique mutations on their autologous
tumor cells.
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